These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 31871513

  • 1. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
    Elhalik M, El-Atawi K, Dash SK, Faquih A, Satyan AD, Gourshettiwar N, Khan A, Varughese S, Ramesh A, Khamis E.
    Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
    [Abstract] [Full Text] [Related]

  • 2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 3. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee.
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [Abstract] [Full Text] [Related]

  • 4. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
    J Manag Care Pharm; 2010 Aug; 16(1):15-22. PubMed ID: 20044843
    [Abstract] [Full Text] [Related]

  • 5. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR, Masaquel AS, Weiner LB, Smith DM, Wade SW, Mahadevia PJ.
    BMC Pediatr; 2014 Oct 13; 14():261. PubMed ID: 25308481
    [Abstract] [Full Text] [Related]

  • 6. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
    Ratti C, Greca AD, Bertoncelli D, Rubini M, Tchana B.
    Ital J Pediatr; 2023 Jan 11; 49(1):4. PubMed ID: 36631870
    [Abstract] [Full Text] [Related]

  • 7. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP, Lee SWH.
    Pharmacotherapy; 2017 Jun 11; 37(6):755-769. PubMed ID: 28423192
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y.
    Eur J Clin Microbiol Infect Dis; 2017 Sep 11; 36(9):1629-1634. PubMed ID: 28391538
    [Abstract] [Full Text] [Related]

  • 9. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH, Scheltema NM, Clerc M, van Houten MA, Nibbelke EE, Achten NB, Arp K, Sanders EAM, Bont LJ, Bogaert D.
    Lancet Respir Med; 2020 Oct 11; 8(10):1022-1031. PubMed ID: 32203712
    [Abstract] [Full Text] [Related]

  • 10. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.
    J Manag Care Pharm; 2010 Oct 11; 16(1):46-58. PubMed ID: 20131495
    [Abstract] [Full Text] [Related]

  • 11. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.
    Turk J Pediatr; 2012 Oct 11; 54(4):344-51. PubMed ID: 23692714
    [Abstract] [Full Text] [Related]

  • 12. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B, Egger B, Kurath-Koller S, Urlesberger B.
    Int J Infect Dis; 2017 Apr 11; 57():50-53. PubMed ID: 28163166
    [Abstract] [Full Text] [Related]

  • 13. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan 11; 90(1):F64-8. PubMed ID: 15613580
    [Abstract] [Full Text] [Related]

  • 14. Cost Savings Without Increased Risk of Respiratory Hospitalization for Preterm Children after the 2014 Palivizumab Policy Update.
    Levin JC, Beam AL, Fox KP, Hayden LP.
    Am J Perinatol; 2024 May 11; 41(S 01):e133-e141. PubMed ID: 35523410
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 16. Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
    Han YM, Seo HJ, Choi SH, Jung YJ, Ahn SY, Yoo HS, Sung SI, Shim JW, Lee YK, Ko SY, Shin SM, Hwang JH, Lee JH, Choi BM, Kim ES, Jeon JH, Kim SS, Chang YS, Park WS.
    J Korean Med Sci; 2015 Jul 30; 30(7):924-31. PubMed ID: 26130956
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
    Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, Sawicky J, Yee J, Moride Y.
    Am J Perinatol; 2024 May 30; 41(S 01):e1107-e1115. PubMed ID: 36452969
    [Abstract] [Full Text] [Related]

  • 18. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P, Composs Investigators.
    Pediatr Infect Dis J; 2002 Jun 30; 21(6):512-8. PubMed ID: 12182374
    [Abstract] [Full Text] [Related]

  • 19. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA, Agouba R, Obaidy IE, Alhabshan F, Abu-Sulaiman R.
    Ann Saudi Med; 2021 Jun 30; 41(1):31-35. PubMed ID: 33550912
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.